The inherited bleeding disorder von Willebrand disease (VWD) is challenging to diagnose owing to disease heterogeneity, lack of a definitive laboratory test and variations in diagnostic criteria. We evaluated the impact of diagnosis and diagnostic delay on patient outcomes. The PharMetrics Plus Database was interrogated for medical claims for VWD (ICD-9 286.4) and bleeding events between 1 January 2006 and 30 June 2015.
diagnosis of VWD on patient outcomes, as assessed by the frequency of bleed-associated claims before and after diagnosis. Additional objectives were to characterize patient care settings, assess time to diagnosis and identify health care-and patient-related factors associated with diagnostic delay.
| METHODS

| Data source
This analysis utilized the Quintiles IMS Real-World Data Adjudicated Claims (PharMetrics Plus) Database, which contains individual-level, de-identified healthcare claims information from health plans on more than 100 million commercially insured patients in the United 
| Analysis populations
The overall VWD patient population included all diagnosed patients, defined as patients with at least two medical claims for VWD. Patients were considered "newly diagnosed" if they had at least 9 months' continuous enrolment in the same health plan before their first VWD claim. Additional criteria for continuous enrolment were applied to generate further samples for longitudinal analysis (Table 1 ).
| Analyses
Patient and healthcare factors were analysed, including demographics, comorbid diagnoses, physician specialty (for diagnosis, bleed care and general VWD management), diagnostic test use, "tipping point" claims (defined as a bleeding event occurring immediately prior to, or at the same time as, the initial VWD diagnosis), and serial misrecognition of VWD (defined as two or more visits with the same specialist type to treat a bleed prior to diagnosis). Patient outcomes were assessed through analysis of bleed frequency and bleed type. Longitudinal analysis of newly diagnosed patients was performed by aligning patients by date of first VWD claim, or assumed date of diagnosis.
| Statistical methods
This study was observational, and no formal hypotheses were tested; therefore, no formal statistical tests were applied. All data are presented descriptively. SAS and R analysis software were used.
| RESULTS
| Patient populations
A total of 32 028 patients with VWD diagnoses were identified.
Longitudinal data sets for newly diagnosed patients with 9, 12, and 24 months of continuous enrolment prior to VWD diagnosis included 18 182, 15 971 and 10 354 patients, respectively (Table 1) . Most (72%) newly diagnosed patients were female (Table 2) . Females outnumbered males in every age group, except for children (aged 0-15 years at diagnosis), and accounted for disproportionately more bleed claims (83% vs 17% of claims). Median (interquartile range) age at VWD diagnosis was 34 (19-49) years for females, and 22 (11-49) years for males.
| Patient journey to VWD diagnosis
Prior to VWD diagnosis, bleeds were most commonly managed by a hospitalist/emergency room (ER) physician (seen by almost half of male and female patients with bleed claims in the 6 months before VWD diagnosis) (Figure 1) . A quarter to a third of female patients sought care from obstetrician/gynaecologists, and a similar proportion from primary care physicians (PCPs), whereas only a fifth of male patients received care from PCPs. In all, 27% of male and female patients with bleed claims within the 6 months prior to diagnosis received care from a haematologist. Hospitalists/ERs were Figure 2 ).
The average time from first bleed claim within the period of enrolment to VWD diagnostic claim was 669 days (range 2-3284 days).
Serial misrecognition of VWD was common, with 25% of patients visiting the same specialist type at least twice for an episodic bleed prior to VWD diagnosis. Of these patients, most (82%) were female, and more than half (54%) were aged 16-45 years; most were treated by an obstetrician/gynaecologist (35%), hospitalist/ER (33%) or PCP (26%).
Two-thirds (66%) of serially misrecognized patients sought care for at least three bleeds in the year before diagnosis, compared with 14% of all patients (Figure 3 ). Heavy menstrual bleeding and epistaxis were the most common bleeding events among serially misrecognized patients and were both more common among this group of patients than among the overall newly diagnosed VWD population. In the 6 months before diagnosis, 37% and 15% of misrecognized female patients had a claim for heavy menstrual bleeding or epistaxis, respectively, compared with 11% and 6% of other patients. In the 2 years prior to diagnosis, 76% of female serially misrecognized patients had claims for heavy menstrual bleeding, and 21% of all serially misrecognized patients had claims for epistaxis.
In all, 41% of female and 27% of male patients had a "tipping point"
claim (a bleeding event occurring immediately prior to, or at the same time as, the initial VWD diagnosis). Among females, 45%, 11% and 7%
of tipping point claims were associated with heavy menstrual bleeding, epistaxis or delayed coagulation/prolonged bleeding, respectively; among males, the most common such claims were epistaxis (40%), delayed coagulation/prolonged bleeding (18%) and haemorrhage complicating a procedure (8%).
The most frequently performed diagnostic test for a bleeding disorder was partial thromboplastin time (used in 53% of patients in the 
| Impact of VWD diagnosis on patient outcomes
The frequency of bleed claims decreased after diagnosis: 41% of females and 26% of males had a bleed in the year prior to diagnosis, which decreased to 32% and 18% in the year after diagnosis, and to 21% and 9% between 1 and 2 years after diagnosis ( Figure 4) . The proportion of patients with multiple bleed claims also decreased (17% of female patients had three or more bleed claims in the year before diagnosis, which fell to 11% in the year following diagnosis, and to 6% in the 1-2 years after diagnosis; the respective figures for males were 7%, 5% and 3%). Both before and after diagnosis, the most common bleed types were heavy menstrual bleeding in women and epistaxis in men ( Figure 5 ). Patients in whom VWD had been serially misrecognized prior to diagnosis continued to have a higher frequency of bleeding episodes than other patients, although bleed frequency was lower than before diagnosis ( Figure 3 ). In the year following diagnosis, 25% of serially misrecognized patients and 9% of all patients had three or more bleed claims.
Claims for gastrointestinal (GI) bleeds did not decrease after VWD diagnosis: these bleeds were experienced by 1% of patients in the 6 months prior to diagnosis, and by 1%-2% of patients in each 6-month interval postdiagnosis through 24 months ( Figure 5 ). Anaemia claims increased initially in the year following VWD diagnosis, but decreased slightly overall over the 2 years following diagnosis. Fifteen percentage of female patients (and 9% of male patients) had anaemia claims in the year prior to diagnosis; this number rose to 19% (12%) in the year after diagnosis and decreased to 13% (5%) in the 2 years after diagnosis. Percentage of patients Percentage of patients F I G U R E 3 Frequency of bleeding episodes among serially misrecognized patients (N=981) and all patients (N=5477) before and after diagnosis of von Willebrand disease (VWD). Serially misrecognized patients had ≥2 visits with the same specialist type to treat a bleed prior to VWD diagnosis. All patients were continuously enrolled in the IMS PharMetrics Plus Database for ≥24 months prior to first VWD diagnosis and for ≥24 months after diagnosis 
F I G U R E 2 Specialists diagnosing von Willebrand disease (VWD) in (A) female patients (N=9793) and (B) males patients (N=3834)
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| Healthcare utilization after VWD diagnosis
In the 2 years after diagnosis, 41% of female and 23% of male patients had at least one claim for bleed care, although the overall frequency of bleed claims declined. More patients continued to receive bleed care from a hospitalist/ER than from other specialists or PCPs (Figure 1 ). In the 2 years after diagnosis, 67% and 65% of female and male patients, respectively, had a claim relating to a general VWD management visit (disease follow-up or counselling). These visits were most commonly managed by a haematologist (35% and 29% of visits in females and males, respectively), although PCPs continued to play a significant role (handling 18% and 20% of visits in females and males).
Overall, however, only 33% of patients visited a haematologist (for bleed care or VWD management) in the 2 years after diagnosis. Of these patients, 65% had been diagnosed by a haematologist, and 35%
were referred to the haematologist after diagnosis. Most saw a haematologist infrequently: 47% of the patients who visited a haematologist had only one visit in the 2-year period postdiagnosis, while 12% had more than five visits (a mean of 0.9 visits per year).
| DISCUSSION
In this longitudinal analysis of medical insurance claims data, patients with VWD had fewer bleeding episodes that required medical care after diagnosis, compared with the period before diagnosis. This observation reinforces the importance of accurate and timely diagnosis of VWD and suggests that diagnosis is a trigger for individualized lifestyle change or initiation of medical therapies to prevent bleeds and/ or for effective self-treatment of bleeds. However, our analysis also showed that misrecognition of VWD is common, with a quarter of patients visiting the same specialist type at least twice for an episodic bleed within a defined time frame before diagnosis. This occurred most frequently among young and middle-aged women, and among patients treated by obstetrician/gynaecologists and PCPs. This group of patients experienced more frequent bleeding episodes than other patients, both before and after VWD diagnosis. The source data did not permit analysis of the type of VWD or of whether bleeding frequency varied by type; however, one could speculate on the accuracy of diagnosis and on whether some serially misrecognized patients who continued to seek care for bleeds might have had a condition other than VWD.
In our data set, the average time to VWD diagnosis from the first bleeding event claim was 1.8 years. This is likely a conservative estimate given that we had visibility only of bleeding events that occurred during the period of patients' continuous enrolment in the health plan;
in some patients, the true onset of symptoms may have been prior to enrolment. In a US Centers for Disease Control and Prevention survey, females with VWD (N=75) reported an average of six bleeding symptoms before VWD diagnosis, and an average time from first symptoms to clinical recognition of a bleeding disorder of 16 years. 8 In a study of 38 females with type 1 VWD, there was delay from initial bleeding symptoms to diagnosis of 4 years. 9 In our analysis, fewer than two-thirds of subjects with VWD had a diagnostic laboratory test within the 2 years before or after diagnosis, which calls into question the accuracy of VWD diagnosis within this population. It is possible that some physicians accepted historic diagnoses of VWD without further retesting, or relied on diagnostic methods that are not part of the typical testing armamentarium. A lack of familiarity of PCPs and non-haematologists with VWD diagnostic testing protocols may increase the likelihood of misdiagnosis.
10
Our findings highlight the need for improvements in patient management from bleeding presentation onward, to reduce the time to VWD diagnosis and to streamline the diagnostic process. In our analysis, only a quarter of patients were managed by a haematologist prior to VWD diagnosis, and only 8% of patients who experienced serial misrecognition of symptomatic VWD before diagnosis were under the care of a haematologist. Education on VWD symptoms and diagnosis should therefore be targetted at non-haematologists, including PCPs, obstetrician/gynaecologists, and hospitalists/ERs. Efforts to standardize diagnosis algorithms and criteria for VWD will also be of value.
In our analysis population, 72% of patients were female, although from a genetic perspective VWD is expected to affect both sexes in equal numbers. Heavy menstrual bleeding (and post-partum haemorrhage) drives more females to seek medical care and receive a diagnosis. 11 However, in a survey of 451 US obstetricians and gynaecologists, only 39% of respondents reported that they would consider a bleeding disorder as a possible cause of heavy menstrual bleeding in women of reproductive age, 12 and Ohio Medicaid data demonstrated that less than 25% of adolescents with heavy menstrual bleeding were screened for inherited bleeding disorders. 13 There is therefore scope for enhancing awareness of VWD as a cause of heavy menstrual bleeding, as well as for increasing awareness of non-menstrual symptoms to drive other patients towards diagnosis. Although the overall frequency of bleeds was reduced in our analysis following VWD diagnosis, GI bleeds did not decrease in frequency. GI bleeding can be more challenging to manage than other bleeding events in VWD, 14 and there is a need for further research into the optimal treatment of patients with recurrent GI bleeding. A specific limitation of the current analysis was that the ICD-9
coding does not provide information on VWD type or distinguish patients with definite VWD from those considered to have "low VWF"; however, we would expect most patients in this analysis to be type 1, which accounts for approximately 75% of symptomatic patients with VWD. 2, 16 Miscoding is another potential limitation of the analysis, but the requirement for at least two medical claims for VWD, and for continuous enrolment 2 years postdiagnosis for longitudinal analyses, should minimize the potential for miscoding of patients with spontaneous bleeding events or another bleeding disorder and ensure confidence in the VWD diagnosis. Furthermore, it is possible that due to concern for loss of insurance due to a pre-existing condition clause, some providers may have not coded patients as having VWD if they had mildly reduced VWF in the low VWF range. The Affordable Care
Act was enacted in 2010, and soon thereafter pre-existing condition exclusion bans were put in place. Finally, in the analysis of this healthcare setting, it is possible that some haematologists were represented as hospitalists, owing to limited information within this data set on physician specialty within hospital settings.
| CONCLUSION
In conclusion, we have shown that outcomes for patients with VWD improve for at least 2 years following a VWD diagnosis, highlighting the importance of timely and accurate diagnosis. However, our analysis also highlighted that a significant proportion of patients experience serial misrecognition of their condition and delayed diagnosis.
Together these findings reinforce the need for greater awareness of symptoms and testing protocols among non-haematologist healthcare practitioners to improve diagnosis and subsequent patient management. 
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